307 related articles for article (PubMed ID: 25655314)
1. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice.
Dahl M; Doyle A; Olsson K; Månsson JE; Marques ARA; Mirzaian M; Aerts JM; Ehinger M; Rothe M; Modlich U; Schambach A; Karlsson S
Mol Ther; 2015 May; 23(5):835-844. PubMed ID: 25655314
[TBL] [Abstract][Full Text] [Related]
2. Expression and secretion of human glucocerebrosidase mediated by recombinant lentivirus vectors in vitro and in vivo: implications for gene therapy of Gaucher disease.
Kim EY; Hong YB; Lai Z; Kim HJ; Cho YH; Brady RO; Jung SC
Biochem Biophys Res Commun; 2004 May; 318(2):381-90. PubMed ID: 15120612
[TBL] [Abstract][Full Text] [Related]
3. Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow.
Nolta JA; Yu XJ; Bahner I; Kohn DB
J Clin Invest; 1992 Aug; 90(2):342-8. PubMed ID: 1379609
[TBL] [Abstract][Full Text] [Related]
4. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
Fabrega S; Lehn P
J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
Barnes S; Xu YH; Zhang W; Liou B; Setchell KD; Bao L; Grabowski GA; Sun Y
PLoS One; 2014; 9(12):e116023. PubMed ID: 25551612
[TBL] [Abstract][Full Text] [Related]
6. Delivery of Glucosylceramidase Beta Gene Using AAV9 Vector Therapy as a Treatment Strategy in Mouse Models of Gaucher Disease.
Du S; Ou H; Cui R; Jiang N; Zhang M; Li X; Ma J; Zhang J; Ma D
Hum Gene Ther; 2019 Feb; 30(2):155-167. PubMed ID: 30122074
[TBL] [Abstract][Full Text] [Related]
7. VP22 enhances the expression of glucocerebrosidase in human Gaucher II fibroblast cells mediated by lentiviral vectors.
Jin GS; Zhu GD; Zhao ZG; Liu FS
Clin Exp Med; 2012 Sep; 12(3):135-43. PubMed ID: 21874584
[TBL] [Abstract][Full Text] [Related]
8. Effect of cellular type on expression of acid beta-glucosidase: implications for gene therapy in Gaucher disease.
Xu YH; Wenstrup R; Grabowski GA
Gene Ther; 1995 Nov; 2(9):647-54. PubMed ID: 8548554
[TBL] [Abstract][Full Text] [Related]
9. Long-term expression of the human glucocerebrosidase gene in vivo after transplantation of bone-marrow-derived cells transformed with a lentivirus vector.
Kim EY; Hong YB; Lai Z; Cho YH; Brady RO; Jung SC
J Gene Med; 2005 Jul; 7(7):878-87. PubMed ID: 15712335
[TBL] [Abstract][Full Text] [Related]
10. Toward gene therapy for Gaucher disease.
Kohn DB; Nolta JA; Weinthal J; Bahner I; Yu XJ; Lilley J; Crooks GM
Hum Gene Ther; 1991; 2(2):101-5. PubMed ID: 1911928
[TBL] [Abstract][Full Text] [Related]
11. Effective cell and gene therapy in a murine model of Gaucher disease.
Enquist IB; Nilsson E; Ooka A; Månsson JE; Olsson K; Ehinger M; Brady RO; Richter J; Karlsson S
Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13819-24. PubMed ID: 16954197
[TBL] [Abstract][Full Text] [Related]
12. Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease.
Sanders A; Hemmelgarn H; Melrose HL; Hein L; Fuller M; Clarke LA
Blood Cells Mol Dis; 2013 Aug; 51(2):109-15. PubMed ID: 23642305
[TBL] [Abstract][Full Text] [Related]
13. Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction.
Mitta B; Rimann M; Ehrengruber MU; Ehrbar M; Djonov V; Kelm J; Fussenegger M
Nucleic Acids Res; 2002 Nov; 30(21):e113. PubMed ID: 12409472
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: a weak and efficient promoter for gene therapy.
Almarza E; Río P; Meza NW; Aldea M; Agirre X; Guenechea G; Segovia JC; Bueren JA
Mol Ther; 2007 Aug; 15(8):1487-94. PubMed ID: 17534266
[TBL] [Abstract][Full Text] [Related]
15. [Molecular diagnosis and gene therapy for Gaucher disease].
Ohashi T
Nihon Rinsho; 1993 Sep; 51(9):2300-7. PubMed ID: 8411706
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model.
Marshall J; McEachern KA; Kyros JA; Nietupski JB; Budzinski T; Ziegler RJ; Yew NS; Sullivan J; Scaria A; van Rooijen N; Barranger JA; Cheng SH
Mol Ther; 2002 Aug; 6(2):179-89. PubMed ID: 12161184
[TBL] [Abstract][Full Text] [Related]
17. Expression of human glucocerebrosidase in murine macrophages: identification of efficient retroviral vectors.
Freas-Lutz DL; Correll PH; Dougherty SF; Xu L; Pluznik DH; Karlsson S
Exp Hematol; 1994 Aug; 22(9):857-65. PubMed ID: 8062885
[TBL] [Abstract][Full Text] [Related]
18. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation.
Dunbar CE; Kohn DB; Schiffmann R; Barton NW; Nolta JA; Esplin JA; Pensiero M; Long Z; Lockey C; Emmons RV; Csik S; Leitman S; Krebs CB; Carter C; Brady RO; Karlsson S
Hum Gene Ther; 1998 Nov; 9(17):2629-40. PubMed ID: 9853529
[TBL] [Abstract][Full Text] [Related]
19. Lentiviral Vector Promoter is Decisive for Aberrant Transcript Formation.
Scholz SJ; Fronza R; Bartholomä CC; Cesana D; Montini E; von Kalle C; Gil-Farina I; Schmidt M
Hum Gene Ther; 2017 Oct; 28(10):875-885. PubMed ID: 28825370
[TBL] [Abstract][Full Text] [Related]
20. Complete restoration of glucocerebrosidase deficiency in Gaucher fibroblasts using a bicistronic MDR retrovirus and a new selection strategy.
Aran JM; Licht T; Gottesman MM; Pastan I
Hum Gene Ther; 1996 Nov; 7(17):2165-75. PubMed ID: 8934230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
